Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Changing Patterns, and Clinical Correlates, of Mutations in Patients with Myelofibrosis over Treatment with Ruxolitinib or Hydroxyurea

Alessandro M. Vannucchi, Annalisa Pacilli, PhD, Giada Rotunno, MSc, PhD, Francesco Mannelli, Chiara Paoli, BiSci, Carmela Mannarelli, MSc, PhD, Annalisa Franci, RN, Tiziana Fanelli, BiSc, Alessandro Pancrazzi, PhD, Francesca Gesullo, MSc, Giuditta Corbizi Fattori, BiSc, Alberto Bosi, MD, Paola Guglielmelli, MD PhD

Blood (2017) 130 (Supplement 1): 4195.

https://doi.org/10.1182/blood.V130.Suppl_1.4195.4195

Published: 2017

Journal Articles

A Distinct Mutation Profile Might Contribute to the Dismal Outcome of Triple Negative Patients with Primary Myelofibrosis

Blood (2017) 130 (Supplement 1): 1657.

https://doi.org/10.1182/blood.V130.Suppl_1.1657.1657

Published: 2017

Journal Articles

Complete Inhibition of STAT5 Phosphorylation Is Achieved By Combination of JAK1/2 and PI3K/mTOR Inhibitors in in Vitro and In Vivo MPN Models

Niccolò Bartalucci, PhD, Laura Calabresi, BiSci, Serena Martinelli, BiSci, Manjola Balliu, PhD, Jean-Luc Villeval, PhD, Francesco Annunziato, PhD, Alessandro M. Vannucchi

Blood (2015) 126 (23): 2824.

https://doi.org/10.1182/blood.V126.23.2824.2824

Published: 2015

Journal Articles

A Greater Mutational Complexity May Contribute to the Differential Prognostic Impact of Type 1/Type 1-like Versus Type 2/Type2-like Calreticulin Mutations in Primary Myelofibrosis

Paola Guglielmelli, MD PhD, Giada Rotunno, MSc, Tiziana Fanelli, MSc, Annalisa Pacilli, PhD, Laura Calabresi, BiSci, Alessandro Pancrazzi, BS, Alessandro M. Vannucchi

Blood (2015) 126 (23): 1627.

https://doi.org/10.1182/blood.V126.23.1627.1627

Published: 2015

Journal Articles

C-Myb Restrains Megakaryopoiesis through the Hsa-MiR-486-3p-Driven Down-Regulation of C-Maf

Elisa Bianchi, PhD, Jenny Bulgarelli, PhD, Giorgia Sacchi, BiSci, Samantha Ruberti, BiSci, Ruggiero Norfo, PhD, Sebastiano Rontauroli, BiSci, Valentina Pennucci, PhD, Roberta Zini, PhD, Simona Salati, PhD, Zelia Prudente, BiSci, Sergio Ferrari, MD, Alessandro M. Vannucchi, MD, Rossella Manfredini, PhD

Blood (2014) 124 (21): 5124.

https://doi.org/10.1182/blood.V124.21.5124.5124

Published: 2014

Journal Articles

A Retrospective Analysis of Safety and Efficacy of Ruxolitinib in CALR-Positive Patients with Myelofibrosis

Paola Guglielmelli, PhD MD, Giada Rotunno, BiSci, Costanza Bogani, PhD, Carmela Mannarelli, MSc, Matthew Squires, PhD, Viktoriya Stalbovskaya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 1853.

https://doi.org/10.1182/blood.V124.21.1853.1853

Published: 2014

Journal Articles

Impact Of Prognostically Detrimental Mutations ( ASXL1, EZH2, SRSF2, IDH1/2 ) On Outcomes In Patients With Myelofibrosis Treated With Ruxolitinib In COMFORT-II

Paola Guglielmelli, PhD MD, Flavia Biamonte, BiSci, PhD, Lisa Pieri, MD PhD, Giada Rotunno, BiSci, Chiara Paoli, BiSci, Rajmonda Fjerza, MD, Enrico Tagliafico, MD PhD, Rossella Manfredini, PhD, Valentina Artusi, MSc, Elena Tenedini, PhD, Lucia Artuso, PhD, Isabella Bernardis, Viktoriya Stalbovskaya, PhD, Matthew Squires, PhD, Claire N Harrison, DM, FRCP, FRCPath, Alessandro M Vannucchi, MD

Blood (2013) 122 (21): 107.

https://doi.org/10.1182/blood.V122.21.107.107

Published: 2013

Journal Articles

Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis

Blood (2013) 122 (21): 104.

https://doi.org/10.1182/blood.V122.21.104.104

Published: 2013

Journal Articles

Somatic and Germ-Line Molecular Characteristics Of Prefibrotic Myelofibrosis

Giovanni Barosi, MD, Elisa Bonetti, BS, Paolo Catarsi, PhD, Margherita Massa, PhD, Rita Campanelli, Biol.Sci, Valentina Poletto, Biol.Sci, Gianluca Viarengo, MD, Laura Villani, Biol.Sci, Gabriela Fois, Biol.Sci, Flavia Biamonte, BiSci, PhD, Giada Rotunno, BiSci, Paola Guglielmelli, PhD MD, Umberto Magrini, MD, Alessandro M Vannucchi, MD, Vittorio Rosti, MD

Blood (2013) 122 (21): 4058.

https://doi.org/10.1182/blood.V122.21.4058.4058

Published: 2013

Journal Articles

A Phase 2 Study Of Ruxolitinib In Patients With Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasm. Preliminary Results

Blood (2013) 122 (21): 1583.

https://doi.org/10.1182/blood.V122.21.1583.1583

Published: 2013

Journal Articles

The PI3K Specific Inhibitor BKM120 Results Effective and Synergizes With Ruxolitinib In Preclinical Models Of Myeloproliferative Neoplasms

Niccolò Bartalucci, PhD, Costanza Bogani, PhD, Serena Martinelli, BiSci, Carmela Mannarelli, BiSci, Jean-Luc Villeval, PhD, Alessandro M. Vannucchi, MD

Blood (2013) 122 (21): 1599.

https://doi.org/10.1182/blood.V122.21.1599.1599

Published: 2013

Journal Articles

Integrative Analysis Of mRNA/miRNA Expression Profiles Identified JARID2 As a Shared Target Of Deregulated Mirnas In Primary Myelofibrosis

Blood (2013) 122 (21): 1600.

https://doi.org/10.1182/blood.V122.21.1600.1600

Published: 2013

Journal Articles

Targeted Cancer Exome Sequencing Discovers Novel Recurrent Mutations In MPN

Elena Tenedini, PhD, Isabella Bernardis, MSc, Valentina Artusi, MSc, Lucia Artuso, PhD, Enrica Roncaglia, PhD, Paola Guglielmelli, PhD MD, Lisa Pieri, PhD MD, Costanza Bogani, PhD, Flavia Biamonte, BiSci, PhD, Elisa Bianchi, PhD, Alessandro Pancrazzi, BiSci, Carmela Mannarelli, BiSci, Tiziana Fanelli, BiSci, Giada Rotunno, BiSci, Guidantonio Malagoli Tagliazucchi, MSc, Sergio Ferrari, MD, Rossella Manfredini, PhD, Alessandro M Vannucchi, MD, Enrico Tagliafico, MD PhD

Blood (2013) 122 (21): 4099.

https://doi.org/10.1182/blood.V122.21.4099.4099

Published: 2013

Journal Articles

Abnormal Expression Of WT1-As, MEG3 and ANRIL Long Non-Coding RNAs In Primary Myelofibrosis and Their Clinical Correlates

Blood (2013) 122 (21): 2845.

https://doi.org/10.1182/blood.V122.21.2845.2845

Published: 2013

Journal Articles

Prognostic Impact of Mutations in a Large Series of Patients with Myelofibrosis

Blood (2012) 120 (21): 431.

https://doi.org/10.1182/blood.V120.21.431.431

Published: 2012

Journal Articles

Regulatory Mrna/Microrna Networks in CD34+ Cells From Primary Myelofibrosis.

Blood (2012) 120 (21): 2854.

https://doi.org/10.1182/blood.V120.21.2854.2854

Published: 2012

Journal Articles

Combined Inhibition of JAK2 and mTOR Signaling Results in Enhanced Efficacy in in-Vitro and Preclinical Mouse Models of JAK2V617F-Driven Myeloproliferative Disease

Alessandro M. Vannucchi, MD, Niccolò Bartalucci, PhD, Costanza Bogani, PhD, Serena Martinelli, BiSci, Lorenzo Tozzi, PhD, Alberto Bosi, MD, Jean-Luc Villeval, PhD

Blood (2012) 120 (21): 708.

https://doi.org/10.1182/blood.V120.21.708.708

Published: 2012

Journal Articles

C-Myb Transactivates the Expression of Erythroid Hsa-miR16-2 Gene,

Elisa Bianchi, PhD, Paola Guglielmelli, MD, Lorenzo Tozzi, BiSci, Costanza Bogani, PhD, Simona Salati, PhD, Roberta Zini, PhD, Ruggiero Norfo, PhD, Valentina Pennucci, PhD, Alessandro M. Vannucchi, M.D., Rossella Manfredini, BiSci, PhD

Blood (2011) 118 (21): 3386.

https://doi.org/10.1182/blood.V118.21.3386.3386

Published: 2011

Journal Articles

Treatment with Ruxolitinib (INCB018424) Induced Changes of Microrna Expression in Granulocytes of Patients with Polycythemia Vera and Essential Thrombocythemia,

Paola Guglielmelli, MD, PhD, Lisa Pieri, MD, Enrico Tagliarico, MD, Roberta Zini, BiSci, Ruggiero Norfo, PhD, Alberto Bosi, Kris Vaddi, PhD, DVM, Timothy Burn, PhD, Nancy Contel, Srdan Verstovsek, MD, PhD, Rossella Manfredini, BiSci, PhD, Alessandro M. Vannucchi, MD

Blood (2011) 118 (21): 3852.

https://doi.org/10.1182/blood.V118.21.3852.3852

Published: 2011

Journal Articles

Inhibitors of PI3K/Akt and/or mTOR Inhibit the Growth of Cells of Myeloproliferative Neoplasms and Synergize with JAK2 Inhibitor and Interferon,

Alessandro M. Vannucchi, MD, Costanza Bogani, PhD, Niccolò Bartalucci, BiSc, Lorenzo Tozzi, BiSci, Serena Martinelli, BiSci, Paola Guglielmelli, MD, PhD, Chiara Paoli, BiSci, Lisa Pieri, MD, Alberto Bosi, MD

Blood (2011) 118 (21): 3835.

https://doi.org/10.1182/blood.V118.21.3835.3835

Published: 2011

NARROW

Changing Patterns, and Clinical Correlates, of Mutations in Patients with Myelofibrosis over Treatment with Ruxolitinib or Hydroxyurea

A Distinct Mutation Profile Might Contribute to the Dismal Outcome of Triple Negative Patients with Primary Myelofibrosis

Complete Inhibition of STAT5 Phosphorylation Is Achieved By Combination of JAK1/2 and PI3K/mTOR Inhibitors in in Vitro and In Vivo MPN Models

A Greater Mutational Complexity May Contribute to the Differential Prognostic Impact of Type 1/Type 1-like Versus Type 2/Type2-like Calreticulin Mutations in Primary Myelofibrosis

C-Myb Restrains Megakaryopoiesis through the Hsa-MiR-486-3p-Driven Down-Regulation of C-Maf

A Retrospective Analysis of Safety and Efficacy of Ruxolitinib in CALR-Positive Patients with Myelofibrosis

Impact Of Prognostically Detrimental Mutations ( ASXL1, EZH2, SRSF2, IDH1/2 ) On Outcomes In Patients With Myelofibrosis Treated With Ruxolitinib In COMFORT-II

Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis

Somatic and Germ-Line Molecular Characteristics Of Prefibrotic Myelofibrosis

A Phase 2 Study Of Ruxolitinib In Patients With Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasm. Preliminary Results

The PI3K Specific Inhibitor BKM120 Results Effective and Synergizes With Ruxolitinib In Preclinical Models Of Myeloproliferative Neoplasms

Integrative Analysis Of mRNA/miRNA Expression Profiles Identified JARID2 As a Shared Target Of Deregulated Mirnas In Primary Myelofibrosis

Targeted Cancer Exome Sequencing Discovers Novel Recurrent Mutations In MPN

Abnormal Expression Of WT1-As, MEG3 and ANRIL Long Non-Coding RNAs In Primary Myelofibrosis and Their Clinical Correlates

Prognostic Impact of Mutations in a Large Series of Patients with Myelofibrosis

Regulatory Mrna/Microrna Networks in CD34+ Cells From Primary Myelofibrosis.

Combined Inhibition of JAK2 and mTOR Signaling Results in Enhanced Efficacy in in-Vitro and Preclinical Mouse Models of JAK2V617F-Driven Myeloproliferative Disease

C-Myb Transactivates the Expression of Erythroid Hsa-miR16-2 Gene,

Treatment with Ruxolitinib (INCB018424) Induced Changes of Microrna Expression in Granulocytes of Patients with Polycythemia Vera and Essential Thrombocythemia,

Inhibitors of PI3K/Akt and/or mTOR Inhibit the Growth of Cells of Myeloproliferative Neoplasms and Synergize with JAK2 Inhibitor and Interferon,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only